Relapse Prevention in Schizophrenia: Caplyta’s Clinical Trial Success
Stefania Longo2024-11-05T18:11:39-05:00News|
This article from Fierce Pharma discusses Intra-Cellular's recent clinical trial success with Caplyta for relapse prevention in schizophrenia.
Featured Webinars
From Clinical Data to Actionable Assets for Pharmaceutical R&D
Tuesday, June 16, 2026
Sponsor: France Tissue Bank
Partner: Scientist.com
Screening the Unscreenable: Expanding the Reach of Drug Discovery
Thursday, June 4, 2026
Sponsor: SandboxAQ
Advertisement
Latest News & Resources
Content Categories
Aging
Analytical Sciences
Animal Behavioral Neuroscience
Auditory Sciences
Cancer & Oncology Research
Cardiovascular
Cell & Molecular Biology
Clinical Research
Corporate News
Drug Discovery & Development
Education & Teaching
Epidemiology & Infectious Disease
General Biology
Genetics & Genomics
Human Physiology
Industry & Career
Lab Animal Sciences
Materials Science
Metabolic Function
Microbiology & Immunology
Microscopy
Muscle Physiology & Function
Neuroscience
Obesity
Pharmacology
Preclinical Imaging
Renal Physiology
Respiratory Science
Sports Science
Toxicology
Value, Evidence, Access
Vascular Biology
Vision Research
